肠道菌群代谢物氧化三甲胺与新发CKD及肾功能下降
在10564名社区成人中,血浆TMAO较高者新发CKD风险更高且年化eGFR下降更快,呈单调剂量反应关系,关联在不同种族/族裔中一致。
要点
- 较高血浆TMAO与新发CKD风险升高相关,最高五分位HR为2.24。
- TMAO较高者年化eGFR下降更快,最高五分位为−0.43 ml/min per 1.73 m2。
- TMAO与eGFR下降的关联不弱于糖尿病、收缩压升高等已知危险因素。
核心结论
- 在社区美国成人中,较高的系列血浆TMAO水平与新发CKD风险升高及年化肾功能下降更快相关。
研究设计与样本
- 研究纳入两个社区前瞻性队列共10564名eGFR≥60 ml/min per 1.73 m2的参与者评估新发CKD。
- 基线及一次随访时用靶向质谱测TMAO,随访中最多四次测肌酐和胱抑素C计算eGFR。
- 新发CKD定义为eGFR较基线下降≥30%且eGFR<60 ml/min per 1.73 m2。
- 采用时变Cox模型和线性混合模型分析,调整社会人口学、生活方式、饮食及心血管危险因素。
主要发现
- 中位随访9.4年(四分位距9.1–11.6年)期间发生979例新发CKD事件。
- 与第一五分位相比,第二至第五五分位新发CKD的HR(95%CI)分别为1.65(1.22–2.23)、1.68(1.26–2.25)、2.28(1.72–3.02)、2.24(1.68–2.98)。
- 与第一五分位相比,第二至第五五分位年化eGFR变化(95%CI)分别为−0.21(−0.32至−0.09)、−0.17(−0.29至−0.05)、−0.35(−0.47至−0.22)、−0.43(−0.56至−0.30)ml/min per 1.73 m2。
- 上述关联呈单调剂量反应关系,且在不同种族/族裔群体中一致。
- TMAO与eGFR下降的关联与糖尿病、收缩压每高10 mmHg、年龄每大10岁及黑人种族等已知CKD危险因素的关联相似或更大。
临床怎么用
- 血浆TMAO可作为社区成人新发CKD和肾功能下降风险的潜在生物标志物。
- 研究结果支持未来开展临床试验,检验降低血浆TMAO水平能否预防CKD发生和进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In community-based US adults, higher plasma trimethylamine N-oxide levels associated with higher risk of incident CKD and greater rate of kidney function decline. Findings from our study support future clinical trials to examine whether lowering plasma trimethylamine N-oxide levels may prevent CKD development and progression. BACKGROUND: Trimethylamine N-oxide (TMAO) is a gut microbiota–derived metabolite of dietary phosphatidylcholine and carnitine. Experimentally, TMAO causes kidney injury and tubulointerstitial fibrosis. Little is known about prospective associations between TMAO and kidney outcomes, especially incident CKD. We hypothesized that higher plasma TMAO levels would be associated with higher risk of incident CKD and greater rate of kidney function decline. METHODS: We included 10,564 participants from two community-based, prospective cohorts with eGFR ≥60 ml/min per 1.73 m2 to assess incident CKD. TMAO was measured using targeted mass spectrometry at baseline and one follow-up visit. Creatinine and cystatin C were measured up to four times during follow-up and used to compute eGFR. Incident CKD was defined as an eGFR decline ≥30% from baseline and a resulting eGFR <60 ml/min per 1.73 m2. Time-varying Cox models assessed the association of serial TMAO measures with incident CKD, adjusting for sociodemographic, lifestyle, diet, and cardiovascular disease risk factors. Linear mixed models assessed the association with annualized eGFR change in 10,009 participants with at least one follow-up eGFR measure without exclusions for baseline eGFR levels. RESULTS: During a median follow-up of 9.4 years (interquartile range, 9.1–11.6 years), 979 incident CKD events occurred. Higher TMAO levels were associated with higher risk of incident CKD (second to fifth versus first quintile hazard ratio [95% confidence interval]=1.65 [1.22 to 2.23], 1.68 [1.26 to 2.25], 2.28 [1.72 to 3.02], and 2.24 [1.68 to 2.98], respectively) and greater annualized eGFR decline (second to fifth versus first quintile annualized eGFR change=−0.21 [−0.32 to −0.09], −0.17 [−0.29 to −0.05], −0.35 [−0.47 to −0.22], and −0.43 [−0.56 to −0.30] ml/min per 1.73 m2, respectively) with monotonic dose–response relationships. These associations were consistent across different racial/ethnic groups examined. The association with eGFR decline was similar to or larger than that seen for established CKD risk factors, including diabetes, per 10 mm Hg of higher systolic BP, per 10 years of older age, and Black race. CONCLUSIONS: In community-based US adults, higher serial measures of plasma TMAO were associated with higher risk of incident CKD and greater annualized kidney function decline.
引用
- Wang M, Tang WHW, Li XS, et al. The Gut Microbial Metabolite Trimethylamine N -oxide, Incident CKD, and Kidney Function Decline. J Am Soc Nephrol. 2024. PMID: 38593157. doi:10.1681/ASN.0000000000000344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。